undamentalytics Newsletter
Sign in

Beam Therapeutics Inc. revenue

Beam Therapeutics Inc.'s revenue was $140m in fiscal 2025, up 120.0% on the year before. Since fiscal 2019 ($18,000) it has grown at a compound 345.0% a year. Over the last twelve months it was $147m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue00526137864140147
Growth on the year before—+33.3%+>999%+17.5%+520.0%−83.2%+120.0%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Beam Therapeutics Inc. $147m 163.3% 21.6%
Karyopharm Therapeutics Inc. $147m 6.8% 0.1%
Agenus Inc $133m 30.5% 10.1%
Immunitybio, Inc. $166m 192.9% 554.3%
Nuvation Bio Inc. $170m 1083.6% —
Mesoblast LTD $120m 599.2% —

Compare with peers

Head to head: BEAM vs KPTIAGEN vs BEAMBEAM vs IBRXBEAM vs NUVB

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Beam Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Beam Therapeutics Inc.